Thursday, April 25, 2024
BigHat Biosciences, a biotech firm specializing in AI-driven antibody discovery and development, has teamed up with Janssen Biotech Inc., a Johnson & Johnson subsidiary, in a strategic collaboration. This partnership combines Johnson & Johnson's expertise in drug discovery, clinical development, and data science with BigHat's Milliner™ platform, which integrates machine learning technologies with a high-speed wet lab. Together, they aim to design and select high-quality antibodies targeting multiple therapeutic Neuroscience targets. The agreement, facilitated by Johnson & Johnson Innovation, promises to push the boundaries of antibody-based therapeutics.
BigHat's Milliner™ platform pioneers a novel approach by merging a synthetic biology-based high-speed wet lab with cutting-edge machine learning techniques. This synergy empowers the platform to engineer antibodies with enhanced functionality and improved biophysical properties, transforming the process of antibody design and discovery. By significantly expediting candidate discovery and validation, this innovative approach holds promise for addressing a spectrum of conditions, from chronic illnesses to life-threatening diseases.
BigHat, expressed enthusiasm about the collaboration, stating, "We're thrilled to partner with Johnson & Johnson to leverage BigHat’s Milliner™ platform for accelerating protein design." He added, "We eagerly anticipate advancing our shared mission of expediting the development of breakthrough therapies for challenging-to-treat diseases."
Source: businesswire.com
